Market Scope

The global glaucoma pharmaceuticals market is highly mature, with most therapies still based on drug classes introduced decades ago. Only a limited number of newer agents have entered in recent years, including Glanatec, Vyzulta, Eybelis, Rhopressa, and Rocklatan. Prostaglandin analogs and prostamides remain the global first-line standard for open-angle glaucoma, but pricing varies dramatically. Branded therapies average around $18/month, yet range from just over $6 in India to nearly $80 in the United States after discounts, while generics average just $7. Fixed-combination drugs, now largely off-patent, sit in between at just over $17, while low-cost beta blockers (just under $5) anchor treatment in price-sensitive markets. As generics expand and payers push cost controls, pricing pressure continues to intensify — especially on high-revenue branded prostaglandins and combination therapies. In some European markets, aggressive negotiations have driven branded prices below US generics, while “buy generic” policies in the United States and Japan further accelerate the shift. At the same time, fixed-combination drugs are gaining traction as glaucoma progresses. By combining multiple mechanisms into a single drop, they simplify treatment and improve compliance, making them an increasingly preferred step-up option in the US and a growing replacement for multi-drug regimens in Europe and Japan. Market Scope's new “2026 Glaucoma Pharmaceuticals Market Report” provides a data-driven view of the global and regional glaucoma drug markets, highlighting the trends and competitive forces shaping future growth. The report includes forecasts through 2031 across all major therapy classes, including prostaglandins (branded and generic), beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combinations, NO-donating compounds, and Rho-kinase inhibitors. In addition, the report examines a robust development pipeline of over 30 drug candidates and profiles 23 leading companies, providing insight into product portfolios, strategic positioning, and future outlook. To learn more about this report or request a sample: 🔗 https://bit.ly/GPh26 📧 matthew@market-scope.com #Glaucoma #Pharma #Market #Ophthalmology #Ophthalmic #Market

The global retinal surgical device market is heavily concentrated in developed regions, where access to specialized care, advanced infrastructure, and trained retina specialists supports the majority of procedure volume and technology adoption. At the same time, large emerging markets are becoming increasingly important growth drivers as aging populations and expanding healthcare investment increase demand for retinal treatment. Wealthy markets—including the United States, Western Europe, Japan, and other high–GDP-per-capita countries such as Canada, South Korea, Taiwan, and Australia—account for roughly two-thirds of the global market. These regions benefit from high healthcare spending, broad access to advanced retinal care, and strong concentrations of retina specialists, making them the primary focus for most manufacturers. China represents the next major growth engine, accounting for about one-fifth of the market, with demand rising as the population ages and investment in eye care expands. In contrast, access to retinal care remains limited in India and Latin America, where services are concentrated in major metro areas and specialist availability is constrained—though these regions represent long-term growth opportunities. The "Rest of World" category presents a more fragmented opportunity. Access to advanced retinal care varies widely, and companies typically focus on key markets such as Russia, Turkey, Egypt, Poland, South Africa, and Ukraine, where adoption is higher but growth can be influenced by economic and geopolitical volatility. The new “2026 Retinal Device Market Report” provides a comprehensive, data-driven analysis of the global retinal device market, including market size, growth trends, and the key developments shaping future demand for major product segments such as vitrectomy machines, vitrectomy packs, accessories and allied surgical products, tamponades, retinal medical devices, maintenance and upgrade revenue, and other surgical devices. It evaluates the current competitive landscape and provides detailed forecasts through 2031, offering clear insight into how the market is expected to evolve over the next five years. To learn more about this report or request a sample: 🔗 https://bit.ly/RetDev26 📧 matthew@market-scope.com #Retina #Device #Surgical #Medical #Market #Ophthalmology #Ophthalmic #Market

Weekly Ophthalmic News Briefing – the latest you need to know: Bayer to Acquire Perfuse Therapeutics in Deal Worth Up to $2.45 Billion: https://bit.ly/4dfpFzl Quarterly Ophthalmic Revenue Roundup for Alcon, Amgen, Hoya, Ocular Therapeutix, Inc., and Xbrane Biopharma AB: https://bit.ly/48S6g6e Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe: https://bit.ly/48SHLGb Xbrane Biopharma AB Resubmits BLA to US FDA for Lucentis Biosimilar: https://bit.ly/4uJW88f Novelty Nobility Inc. Taps AGC Biologics to Help Advance Bispecific Retinal Candidate: https://bit.ly/4ffa59v Kubota Vision, Laboratoires KÔL Team Up on Compassionate Use of Stargardt Candidate: https://bit.ly/48X1e8G US FDA Accepts Opus Genetics’ LCA5 Gene Therapy Candidate into New Rare Disease Program: https://bit.ly/4dAvRDj Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma

India’s ophthalmic market is projected to expand steadily through 2030, with Market Scope forecasting nearly 6 percent annual growth from $1.6 billion in 2025 to more than $2.0 billion. Growth will be supported by an aging population, improving access to care, broader insurance coverage, and increasing demand for treatment of chronic eye diseases. Diagnostic equipment currently represents the largest segment of India’s ophthalmic market, reflecting continued investment in infrastructure, earlier disease detection, and expanding access to eye care. Cataract, however, is expected to become the leading segment by 2030 as procedure volumes rise and insurance coverage broadens. Retina also represents a significant growth opportunity, supported by increased use of anti-VEGF therapies and biosimilars, while government initiatives aimed at expanding glaucoma care continue to drive rapid growth in that segment. India’s strong economic outlook, rising life expectancy, and expanding middle class are increasing demand for both essential and elective eye care. Combined with large unmet need and continued investment in infrastructure and technology, these factors are shifting India’s eye care system toward broader disease management—supporting sustained growth across the ophthalmic market. Market Scope's "2025 India Ophthalmic Market Report" provides a comprehensive analysis of India’s ophthalmic market, highlighting key trends, competitive dynamics, and factors shaping future growth. The report includes forecasts for disease prevalence, procedure volumes, and technology adoption across diagnostic equipment, lasers, cataract, refractive, cornea, glaucoma, retina, dry eye, surgical instruments, and single-use surgical devices. For more information about this report or to request a sample, please visit the product page or email matthew@market-scope.com. To learn more about this report or request a sample: 🔗 https://bit.ly/IndiaOMR25 📧 matthew@market-scope.com #India #Ophthalmic #Market #Ophthalmology #DiagnosticEquipment #Cataract #IOL #Retina #AntiVEGF

Weekly Ophthalmic News Briefing – the latest you need to know: Q1-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Regeneron, Glaukos Corporation, Astellas Pharma, Novartis, and Lumibird Medical: https://bit.ly/4n8hold Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells: https://bit.ly/48EQ9sI Ligand Pharmaceuticals to Acquire XOMA Royalty, Including its Vabysmo Royalties, for $739 Million: https://bit.ly/48DDaHG Belite Bio Initiates Rolling NDA Submission for Oral Tinlarebant in Stargardt: https://bit.ly/4tSMWOO BVI Medical Announces Full CE Marking for its Virtuoso Platforms: https://bit.ly/4diRwQp US FDA Gives Green Light to Trial of LayerBio, Inc’s OcuRing-K for Post-op Inflammation and Pain: https://bit.ly/4cXLwN3 Formosa Pharmaceuticals, Inc., Singapore Eye Research Institute (SERI) to Explore New Treatments for Corneal, Ocular Surface Disease: https://bit.ly/4d54srU EMA Grants PRIME Designation to Ray Therapeutics, Inc.’s Optogenetic RP Candidate: https://bit.ly/4uuZCLK Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma

The April edition of Market Scope’s Ophthalmic Market Perspectives newsletter is out now, featuring new survey insights, M&A activity, and the latest product and clinical developments shaping ophthalmology. This issue includes exclusive findings from Market Scope’s new optometrist survey on how ODs educate patients about premium IOLs prior to referral, along with key policy updates—from the EU easing MDR transition timelines to a New Hampshire veto blocking expanded OD scope. Coverage also highlights major deal activity, including Biogen’s $5.6B acquisition of Apellis Pharmaceuticals, Cencora’s acquisition of EyeSouth Partners, Halma plc’s purchase of SURGISTAR, INC., and MeiraGTx reacquiring its XLRP gene therapy candidate from Johnson & Johnson. Fundraising trends are also covered, with Q1-2026 showing a slowdown overall, even as Life Biosciences led recent activity with an $80 million Series D. Product and technology updates include Bausch + Lomb’s preloaded enVista Envy trifocal IOL launch in Europe, Tenpoint Therapeutics, Ltd.’s US rollout of Yuvezzi presbyopia drops, and a wave of new devices from recent meetings. Additional highlights include continued incremental innovation in vitrectomy systems and the first human cataract surgery using ForSight Robotics’ platform. This edition also includes 11 clinical trial updates, three fundraising developments, and profiles of emerging companies including Long Bridge Medical, Inc, i-Lumen Scientific, Inc., SIGNABLOK, INC., Artelo Biosciences, Inc., ReVision Implant, and Super Vision Technology. Subscribe today for timely intelligence on the trends shaping ophthalmology:  🔗 https://bit.ly/MSOMP  📧 matthew@market-scope.com #Ophthalmology #Ophthalmic #Market #IOL #Presbyopia #Retina #GeneTherapy #MDR #Innovation #IndustryNews

Weekly Ophthalmic News Briefing – the latest you need to know: New Law in Tennessee Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy: https://bit.ly/4tFBnKK Inventors of #Luxturna Win $3 Million Breakthrough Prize: https://bit.ly/4tBgJLD Roche Reports Q1-2026 Vabysmo Sales of $1.3 Billion: https://bit.ly/4mW8yHo US CMS Issues J-Codes and Q-Codes for Four Ophthalmic Products in Q1-2026: https://bit.ly/4ejd2FP Revenio Group Oyj Group to Acquire Visionix in $341 Million Deal: https://bit.ly/4mSrYgl US FDA Approves #Vabysmo for Extended Dosing Beyond 6 Months in RVO: https://bit.ly/4t4g305 LENZ Therapeutics Submits Marketing Application for Vizz Presbyopia Drop in the UK: https://bit.ly/42wTfeD Santen to Market Five of AbbVie’s Glaucoma Drops in China: https://bit.ly/3R60oQA Theialife Names Tom Ruggia as President, CEO, Readies Phase III Oral Myopia Candidate Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma

Weekly Ophthalmic News Briefing – the latest you need to know: MeiraGTx Pays Johnson & Johnson $25 Million to Buy Back Gene Therapy Candidate for XLRP: https://bit.ly/3Qis1G0 Johnson & Johnson Reports Q1-2026 Surgical Vision Revenue of $396 Million: https://bit.ly/3QnFoVh K.C. Pharmaceuticals, Inc. Recalls 3.1 Million Eye Drop Bottles over Sterility Concerns: https://bit.ly/4tU1qgQ Pioneering Eye Charities Cure Blindness Project and The Fred Hollows Foundation Team Up to Provide Cataract Surgery in Rwanda, Laos: https://bit.ly/4tnOkIL OCULUS Optikgeräte GmbH - International Launches Pentacam Cornea OCT in US: https://bit.ly/4cCwpHh Bausch + Lomb Gains US FDA Clearance for Bi-Blade+ Cutter and Adaptive Fluidics Update: https://bit.ly/4sLMj8a Halma plc Acquires SURGISTAR, INC. to Augment MicroSurgical Technology's Ophthalmic Instrument Portfolio: https://bit.ly/41PrSwa LUMIBIRD : the specialist in laser technologies to Acquire Malaysian Distributor, Establish Southeast Asian Hub: https://bit.ly/48IdxW6 US FDA Grants Orphan Drug Status to Drug Farm’s ROSAH Candidate: https://bit.ly/4tYObvg Nordic Pharma Now Includes Cannulas with Lacrifill, Marks US Milestone: https://bit.ly/4mH0hXr US FDA Grants Orphan Drug Status to SIGNABLOK, INC.’s ROP Candidate: https://bit.ly/4cxTT03 EMA Grants PRIME Designation to Oculis’ Privosegtor for Optic Neuritis: https://bit.ly/4cCwvi7 US FDA Grants RMAT Status to Ray Therapeutics, Inc.’s Optogenetic RP Candidate: https://bit.ly/4tnYVUl Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma

A wave of new IOL launches from Alcon, Johnson & Johnson | Vision, and BVI Medical throughout the three-day #ASCRS2026 Meeting highlighted intensifying competition across the premium IOL space, Market Scope industry veteran Anthony (Tony) Ingenito reports. Explore where the IOL market is headed in our 2026 IOL Market Report, delivering detailed forecasts, competitive analysis, and global insights across 11 IOL categories. Learn more and request a sample: https://bit.ly/26IOL #Ophthalmology #CataractSurgery #Premium #IOLs #ASCRS

Weekly Ophthalmic News Briefing – the latest you need to know: Alcon Launches Clareon TruPlus Enhanced Monofocal IOL at #ASCRS2026: https://bit.ly/3Q4XkE4 US FDA Approves EYLEA HD® (aflibercept) Injection HCP for Extended Dosing Intervals up to 5 Months: https://bit.ly/4dFR3sh Bausch + Lomb Launches Preloaded enVista Envy Trifocal IOL in Europe: https://bit.ly/4clQwtb STAAR Surgical Reports Preliminary Q1-2026 Net Sales of More Than $90 Million: https://bit.ly/47TT1BB First Human Cataract Surgery Performed with ForSight Robotics’ Robotic Aid: https://bit.ly/3Q67RyO Haag-Streit Announces Global Launch of Metis 3D Digital Heads-Up Module: https://bit.ly/4vp3jDI Cellution Biologics Inc. Launches OptiCover Amniotic Graft at ASCRS Meeting: https://bit.ly/4svUfuk US FDA Gives Green Light to Trial of i-Lumen Scientific, Inc.’s Bioelectric Stimulation Device for Dry AMD: https://bit.ly/4ep6TYm Lenstec, Inc. Appoints Blake D. Michaels as Chief Executive Officer: https://bit.ly/4mqjY5P Tenpoint Therapeutics, Ltd. Appoints Stephen Lane, MD, as Chief Medical Officer: https://bit.ly/4t9F37i Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG